{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:52:30Z","timestamp":1791571950176,"version":"4.3.4"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:p>\n                    Systemic sclerosis (SSc) is a rare, complex, chronic, progressive, severe, often life-threatening, fibrosing, heterogeneous autoimmune connective tissue disease with immune dysfunction and limited treatment options. Interstitial lung disease (ILD) is common in SSc. To study the clinical characteristics of systemic sclerosis-associated interstitial lung disease (SSc-ILD) will provide evidence for the early diagnosis, treatment decision-making, and prognosis of SSc-ILD patients. One hundred and seventy-five patients with SSc were retrospectively enrolled and divided into SSc-ILD group and SSc-non-ILD group. The general clinical characteristics, autoantibodies, laboratory test, thorax high-resolution computed tomography (HRCT), pulmonary function testing, stratification, and treatment options were compared between the 2 groups. The risk factors of SSc-ILD were also analyzed. One hundred and twenty-four SSc-ILD patients (70.9%) and 51 SSc-non-ILD patients (29.1%) were in 175 SSc patients. Raynaud phenomenon, skin swelling, and joint involvement were the top 3 initial symptoms. Sixty-seven SSc-ILD patients (54.1%) showed new onset or progression of ILD on HRCT, which were heterogeneous. The significantly increased indicators in SSc-ILD group were gastrointestinal involvement (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003), antinuclear antibody (ANA) (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006), anti-Scl-70 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001), anti-SSA (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008), and rheumatoid factor (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.04), erythrocyte sedimentation rate (ESR) (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005), CRP (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.000), IL-6 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.001), globulin (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006), IgG (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), IgA (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.001), while the decreased indicators were mean corpusular hemoglobin concerntration (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.036), albumin (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.046), liver dysfunction (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.018), and FVC% (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006). Positive anti-Scl-70 antibody and decreased FVC% were independent risk factors for SSc-ILD. The incidence of ILD occurrence and progression was significantly higher in patients with anti-Scl-70 antibody, diffuse cutaneous systemic sclerosis (dcSSc) plus anti-Scl-70 antibody, ESR\u2005\u226550\u2009mm\/h, and CRP\u2005\u22655.00\u2009mg\/L (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05). Based on the predictive factors (gastrointestinal involvement, joint involvement, positive anti-Scl-70 antibody, liver dysfunction, duration of disease, FVC%, mean corpusular hemoglobin concerntration, ESR, CRP, IgG, IgA, globulin, and albumin), independent risk factors (anti-Scl-70 antibody and decreased FVC%), clinical phenotypic and autoantibody stratification, HRCT heterogeneity, and atypical initial symptoms, it may be seized the \u201cwindow of opportunity\u201d with early diagnosis may exist for preventing the irreversible progression of pulmonary fibrosis of SSc-ILD patients.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047876","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:03:10Z","timestamp":1773043390000},"page":"e47876","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective analysis of clinical characteristics of systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3669-998X","authenticated-orcid":false,"given":"Xin","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Qilu Hospital, Shandong University, Jinan, Shandong Province, China"},{"name":"Department of Rheumatology, Jinan Fourth People\u2019s Hospital, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Qilu Hospital, Shandong University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Northeast International Hospital Houde Hospital, Shenyang, Liaoning Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Weifang People\u2019s Hospital, Weifang, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Qilu Hospital, Shandong University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-201X","authenticated-orcid":false,"given":"Zhang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2 Suppl","key":"R1-20261009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2397198319899013","article-title":"Therapeutic molecular targets of SSc-ILD.","volume":"5","author":"Zhang","year":"2020","journal-title":"J Scleroderma Related Disord"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/ph16081066","article-title":"Novel therapeutic strategies in the treatment of systemic sclerosis.","volume":"16","author":"Gumkowska-Sroka","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis.","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/14712598.2023.2196009","article-title":"Advances in biological and targeted therapies for systemic sclerosis.","volume":"23","author":"Mulcaire-Jones","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.3390\/diagnostics13213332","article-title":"A multidisciplinary approach as a goal for the management of complications in systemic scleroderma: a literature review and case scenario.","volume":"13","author":"P\u0103tr\u00eenta\u0219u","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s10067-024-06936-1","article-title":"Phenotypes of patients with systemic sclerosis in the Chinese Han population: a cluster analysis.","volume":"43","author":"Zhao","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/OARRR.S285409","article-title":"Predicting the progression of very early systemic sclerosis: current insights.","volume":"14","author":"Bellocchi","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/07853890.2023.2179659","article-title":"Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease.","volume":"55","author":"Jang","year":"2023","journal-title":"Ann Med"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis.","volume":"78","author":"Guler","year":"2023","journal-title":"Thorax"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.3390\/jcm12206680","article-title":"The impact of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease.","volume":"12","author":"Mart\u00edn-L\u00f3pez","year":"2023","journal-title":"J Clin Med"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease.","volume":"201","author":"Khanna","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/10600280231213672","article-title":"Systemic-sclerosis-related interstitial lung disease: a review of the literature and recommended approach for clinical pharmacists.","volume":"58","author":"Ferrari","year":"2023","journal-title":"Ann Pharmacother"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease.","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MCP.0000000000000901","article-title":"Recent advances in the management of systemic sclerosis-associated interstitial lung disease.","volume":"28","author":"Hoffmann-Vold","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/biomedicines10010163","article-title":"Systemic sclerosis: from pathophysiology to novel therapeutic approaches.","volume":"10","author":"Benfaremo","year":"2022","journal-title":"Biomedicines"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice.","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/14656566.2023.2198640","article-title":"Pharmacological management of systemic sclerosis associated interstitial lung disease.","volume":"24","author":"Dixon","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/resp.13084","article-title":"Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.","volume":"22","author":"Cheng","year":"2017","journal-title":"Respirology"},{"key":"R20-20261009","doi-asserted-by":"crossref","DOI":"10.3791\/60300","article-title":"Imaging features of systemic sclerosis-associated interstitial lung disease.","author":"Chung","year":"2020","journal-title":"J Vis Exp"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OARRR.S403403","article-title":"Diagnostic performance of anti-topoisomerase-I, anti-Th\/To antibody and anti-fibrillarin using immunoblot method in systemic sclerosis related interstitial lung disease patients.","volume":"15","author":"Logito","year":"2023","journal-title":"Open Access Rheumatol"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/BOR.0000000000000323","article-title":"Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis.","volume":"28","author":"Molberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.1016\/j.intimp.2023.109723","article-title":"Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis.","volume":"116","author":"Bellamri","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"1246777","DOI":"10.3389\/fimmu.2023.1246777","article-title":"Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.","volume":"14","author":"Motta","year":"2023","journal-title":"Front Immunol"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/1744666X.2023.2198212","article-title":"Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.","volume":"19","author":"Makol","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"e003426","DOI":"10.1136\/rmdopen-2023-003426","article-title":"Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.","volume":"9","author":"Petelytska","year":"2023","journal-title":"RMD Open"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/BOR.0000000000000970","article-title":"Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches.","volume":"35","author":"Lescoat","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"R28-20261009","first-page":"1567","article-title":"Systemic sclerosis: one year in review 2023.","volume":"41","author":"Di Battista","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/rheumatology\/keac639","article-title":"Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort.","volume":"62","author":"Ramahi","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","article-title":"Systemic sclerosis interstitial lung disease: unmet needs and potential solutions.","volume":"20","author":"Liakouli","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/resp.70024","article-title":"Quantitative assessment of systemic sclerosis-related interstitial lung disease via 3D-imaging.","volume":"30","author":"Nakayasu","year":"2025","journal-title":"Respirology"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/diagnostics11111960","article-title":"High-resolution computed tomography: lights and shadows in improving care for SSc-ILD patients.","volume":"11","author":"Ruaro","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R35-20261009","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.resinv.2025.01.001","article-title":"Clinical significance of histological inflammation in systemic sclerosis-associated interstitial lung disease.","volume":"63","author":"Hirota","year":"2025","journal-title":"Respir Investig"},{"key":"R36-20261009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2397198320970394","article-title":"The role of ultrasound in systemic sclerosis: on the cutting edge to foster clinical and research advancement.","volume":"6","author":"Hughes","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"R37-20261009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12931-025-03117-9","article-title":"Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients.","volume":"26","author":"Guiot","year":"2025","journal-title":"Respir Res"},{"key":"R38-20261009","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00296-024-05681-7","article-title":"Use of artificial intelligence algorithms to analyse systemic sclerosis-interstitial lung disease imaging features.","volume":"44","author":"Zhao","year":"2024","journal-title":"Rheumatol Int"},{"key":"R39-20261009","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/acr.25070","article-title":"Association of symptoms of gastroesophageal reflux, esophageal dilation, and progression of systemic sclerosis-related interstitial lung disease.","volume":"75","author":"Volkmann","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R40-20261009","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/jpm13091334","article-title":"In systemic sclerosis patients, peripheral blood CD21low B cells and serum IL-4 and IL-21 influence joint involvement.","volume":"13","author":"Pellicano","year":"2023","journal-title":"J Pers Med"},{"key":"R41-20261009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rdc.2023.01.008","article-title":"Treatment of inflammatory arthritis in systemic sclerosis.","volume":"49","author":"Kayser","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"R42-20261009","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/thorax-2023-220820","article-title":"Outcomes of systemic sclerosis associated interstitial lung disease patients with a persistent inflammatory phenotype based on serial CRP measurements.","volume":"78","author":"Volkmann","year":"2023","journal-title":"Thorax"},{"issue":"Suppl 3","key":"R43-20261009","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.5152\/eurjrheum.2020.19065","article-title":"Biomarkers as an opportunity to stratify for outcome in systemic sclerosis.","volume":"7","author":"Abignano","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R44-20261009","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/rheumatology\/kead583","article-title":"Towards the use of serum biomarkers in routine management of systemic sclerosis-associated interstitial lung disease.","volume":"63","author":"Elhai","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R45-20261009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/cei.13611","article-title":"Serum and urine free light chains measurements in patients with systemic sclerosis: novel biomarkers for disease activity.","volume":"205","author":"Gigante","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"R46-20261009","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/rheumatology\/keaa747","article-title":"Immunoglobulin G of systemic sclerosis patients programs a pro-inflammatory and profibrotic phenotype in monocyte-like THP-1 cells.","volume":"60","author":"Murthy","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R47-20261009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2230.2007.02678.x","article-title":"Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.","volume":"33","author":"Komura","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"R48-20261009","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11398","article-title":"The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis.","volume":"4","author":"Jandali","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R49-20261009","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12890-025-03713-x","article-title":"Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database.","volume":"25","author":"Kondoh","year":"2025","journal-title":"BMC Pulm Med"},{"key":"R50-20261009","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12890-024-03361-7","article-title":"Usefulness of monitoring mycophenolic acid exposure in systemic sclerosis-related interstitial lung disease: a retrospective cohort study.","volume":"24","author":"Milesi","year":"2024","journal-title":"BMC Pulm Med"},{"key":"R51-20261009","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10067-025-07323-0","article-title":"Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: a multicenter retrospective study.","volume":"44","author":"Misirci","year":"2025","journal-title":"Clin Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:09:00Z","timestamp":1791569340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047876","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2025-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}